Buɗe Madaidaicin Jiyya don NSCLC tare da Babban Gwajin maye gurbin EGFR

Ciwon daji na huhu ya kasance kalubalen kiwon lafiya a duniya, a matsayin na biyu mafi yawan kamuwa da cutar kansa. A cikin 2020 kadai, an sami sabbin kararraki sama da miliyan 2.2 a duk duniya. Ciwon daji na huhu mara ƙarami (NSCLC) yana wakiltar fiye da kashi 80 cikin 100 na duk cututtukan daji na huhu, yana nuna buƙatar gaggawa na dabarun magani da aka yi niyya.

Sauye-sauyen EGFR sun fito a matsayin ginshiƙi a cikin keɓaɓɓen jiyya na NSCLC. EGFR tyrosine kinase inhibitors (TKIs) suna ba da tsarin juyin juya hali ta hanyar toshe siginar ciwon daji, hana ci gaban ƙwayar cuta, da haɓaka mutuwar ƙwayar cutar kansa-duk yayin da rage lalacewar ƙwayoyin lafiya.

Jagoran jagororin asibiti, gami da NCCN, yanzu sun ba da umarnin gwajin maye gurbin EGFR kafin fara maganin TKI, tabbatar da cewa majinyata masu dacewa sun karɓi magungunan da suka dace tun farkon farawa.

Sauye-sauyen EGFR sun fito a matsayin ginshiƙi a cikin keɓaɓɓen jiyya na NSCLC. EGFR tyrosine kinase inhibitors (TKIs) suna ba da tsarin juyin juya hali ta hanyar toshe siginar ciwon daji, hana ci gaban ƙwayar cuta, da haɓaka mutuwar ƙwayar cutar kansa-duk yayin da rage lalacewar ƙwayoyin lafiya.

Jagoran jagororin asibiti, gami da NCCN, yanzu sun ba da umarnin gwajin maye gurbin EGFR kafin fara maganin TKI, tabbatar da cewa majinyata masu dacewa sun karɓi magungunan da suka dace tun farkon farawa.

Gabatar da EGFR Gene 29 Kit ɗin Gane Maɓalli (Fluorescence PCR)
Gano Madaidaicin Gano don Amintattun Shawarwari na Jiyya

Kit ɗin ganowa na EGFR na Macro & Micro-Test yana ba da damar gano sauri da daidaitaccen maɓalli na maɓalli 29 a cikin exons 18-21 a cikin nama da biopsies na ruwa-ƙarfafawa likitocin asibiti don daidaita jiyya tare da kwarin gwiwa.

Me yasa ZabiMacro & Micro-Test'sKit ɗin Gwajin EGFR?

Kit ɗin yana gano 29 na gama-gari na EGFR na yau da kullun a cikin exons 18-21 daga nama ko samfuran jini na marasa lafiya NSCLC, wanda ke rufe hankalin miyagun ƙwayoyi da wuraren juriya don jagorantar amfani da magungunan da aka yi niyya kamar gefitinib da osimertinib.

1. 1.Ingantattun Fasahar ARMS: Ingantaccen ARMS tare da haɓaka mai haɓakawa don ƙayyadaddun ƙayyadaddun bayanai;
2. 2.Enzymatic Enrichment: Rage nau'in nau'in daji ta hanyar narkewar enzymatic, inganta daidaiton ganowa da rage ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun kwayoyin halitta;
3. 3.Temperature Blocking: Yana ƙara ƙayyadaddun matakan zafin jiki a cikin tsarin PCR, rage rashin daidaituwa da haɓaka daidaiton ganewa;
4. 4.High Sensitivity: Gano maye gurbi kamar yadda 1% maye gurbi;
5. 5.Great Accuracy: Ciki na ciki da kuma UNG enzyme don rage girman sakamakon ƙarya;
6. 6.Efficiency: Sakamakon sakamako a cikin 120 min
7. 7.Dual Samfurin Taimako - An inganta shi don duka nama da samfurori na jini, yana ba da sassauci a cikin aikin asibiti.
8. 8.Wide dacewa: Yadu dacewa tare da kayan aikin PCR na yau da kullum akan kasuwa;
9. 9.Shelf-ray: 12 months.

Maganin Jagora tare da Amincewa
Kit ɗin yana taimakawa don haɓaka sakamakon asibiti kuma ya ci gaba da juriya tare da mahimmancin hankali da juriya.

Fadada Fayil ɗin Fayil ɗin Oncology Madaidaicin ku
Bincika cikakken kewayon hanyoyin gano maye gurbi don KRAS, BRAF, ROS1, ALK, BCR-ABL, TEL-AML1, da ƙari-duk an ƙirƙira su don tallafawa cikakkiyar kulawa mai sarrafa biomarker.

Ƙara koyo:https://www.mmtest.com/oncology/

Contact our team: marketing@mmtest.com